Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29597435 | 1.00 | SIGMAR1 (0.54) | SIGMAR1MAPTCHRNB2CHRNA4KDM4E | |
| Hydrochloric Acid SCHEMBL23538210 | 0.98 | SIGMAR1 (0.52) | SIGMAR1MAPTCHRNB2CHRNA4KDM4E | |
| Hydrochloric Acid SCHEMBL30951854 | 0.98 | SIGMAR1 (0.52) | SIGMAR1MAPTCHRNB2CHRNA4KDM4E | |
| SCHEMBL7020285 | 0.94 | SIGMAR1 (0.57) | SIGMAR1MAPTCHRNB2CHRNA4KDM4E | |
| SCHEMBL549069 | 0.87 | — | — | |
| SCHEMBL29844361 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL4461424 | 0.85 | CHRNB2 (0.55) | SIGMAR1MAPTCHRNB2CHRNA4GAA | |
| SCHEMBL3414893 | 0.83 | SIGMAR1 (0.54) | SIGMAR1MAPTCHRNB2CHRNA4KDM4E | |
| SCHEMBL7019778 | 0.78 | SIGMAR1 (0.57) | SIGMAR1MAPTCHRNB2CHRNA4KDM4E | |
| SCHEMBL10205529 | 0.76 | SIGMAR1 (0.55) | SIGMAR1MAPTCHRNB2CHRNA4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 608 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024148210-A1 | CYCLIN-DEPENDENT KINASE 12 MODULATORS AND THERAPEUTIC USES THEREOF | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | WO | claimed |
| EP-1839659-A2 | Chemicals compounds | GLAXO GROUP LIMITED (GB) | 2007-10-03 | — | — | EP | claimed |
| EP-1395606-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LTD (GB) | 2007-05-02 | — | — | EP | claimed |
| US-20060160886-A1 | Synergistic mixtures of 6-Chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide and 4-chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide; improved oral bioavailability and pharmacokinetics | GLAXO GROUP LIMITED (GB) | 2006-07-20 | — | — | US | claimed |
| US-20040152697-A1 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2004-08-05 | — | — | US | claimed |
| EP-1395606-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-03-10 | — | — | EP | claimed |
| WO-2002100886-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2002-12-19 | — | — | WO | claimed |
| US-20250320213-A1 | Nitrogen-Containing Heterocyclic Compounds | PFIZER INC. (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250230155-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2025-07-17 | — | — | US | disclosed |
| US-20250154288-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-05-15 | — | — | US | disclosed |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-12134602-B2 | (−)-huperzine A processes and related compositions and methods of treatment | YALE UNIVERSITY (US) | 2024-11-05 | — | — | US | disclosed |
| WO-2024220641-A1 | 1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 USEFUL FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2002-04-25 | — | — | US | disclosed |
| WO-2001040215-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| US-6103738-A | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0877734-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RES & DEV (IE) | 2000-07-12 | — | — | EP | disclosed |
| EP-0877734-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-11-18 | — | — | EP | disclosed |
| WO-1997023462-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-07-03 | — | — | WO | disclosed |
| EP-0321191-A2 | Heterocyclic-substituted quinoline-carboxylic acids | PFIZER INC. (US) | 1989-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154288-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | CCR2, CCRL2, CCR5 | SIGMAR1 1303/4885MAPT 4629/4885CHRNB2 1341/4885 |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, IDH3B | SIGMAR1 466/4885MAPT 2957/4885CHRNB2 688/4885 |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | SIGMAR1 3601/4885MAPT 2661/4885CHRNB2 4108/4885 |
| US-12134602-B2 | (−)-huperzine A processes and related compositions and methods of treatment | CHRNA5, HTR2A, GRIK5 | SIGMAR1 952/4885MAPT 206/4885CHRNB2 33/4885 |
| US-20250320213-A1 | Nitrogen-Containing Heterocyclic Compounds | HRH4, HNMT, NNT | SIGMAR1 2650/4885MAPT 11/4885CHRNB2 3324/4885 |
| US-20040152697-A1 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | TFPI, SERPINC1, TFPI2 | SIGMAR1 4536/4885MAPT 4534/4885CHRNB2 4539/4885 |
| US-20060160886-A1 | Synergistic mixtures of 6-Chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide and 4-chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide; improved oral bioavailability and pharmacokinetics | SULT1E1, SULT1A1, SULT2A1 | SIGMAR1 554/4885MAPT 4244/4885CHRNB2 2762/4885 |
| US-20250230155-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | CHRM5, CHRM4, CHRM1 | SIGMAR1 166/4885MAPT 772/4885CHRNB2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.